Adrenalectomy alters the sensitivity of the central nervous system melanocortin system.
Removal of adrenal steroids by adrenalectomy (ADX) reduces food intake and body weight in rodents and prevents excessive weight gain in many genetic and dietary models of obesity. Thus, glucocorticoids appear to play a key role to promote positive energy balance in normal and pathological conditions. By comparison, central nervous system melanocortin signaling provides critical inhibitory tone to regulate energy balance. The present experiments sought to test whether glucocorticoids influence energy balance by altering the sensitivity to melanocortin receptor ligands. Because melanocortin-producing neurons are hypothesized to be downstream of leptin in a key weight-reducing circuit, we tested rats for their sensitivity to leptin and confirmed reports that the hypophagic response to third ventricular (i3vt) leptin is increased in ADX rats and is normalized by glucocorticoid replacement. Next we tested rats for their sensitivity to the melanocortin agonist melanotan II and found that, as for leptin, ADX enhanced the hypophagic response via a glucocorticoid-dependent mechanism. The central nervous system melanocortin system is unique in that it includes the endogenous melanocortin receptor antagonist, AgRP. The orexigenic effect of i3vt AgRP was absent in ADX rats and restored by glucocorticoid replacement. We conclude that the potent weight-reducing effects of ADX likely involve heightened responsiveness to melanocortin receptor stimulation.
Drazen
Deborah L
DL
Department of Psychiatry, University of Cincinnati, Cincinnati, Ohio 45237, USA. debbie.drazen@uc.edu
Wortman
Matthew D
MD
Schwartz
Michael W
MW
Clegg
Deborah J
DJ
van Dijk
Gertjan
G
Woods
Stephen C
SC
Seeley
Randy J
RJ
D000315:Adrenalectomy; D054369:Agouti-Related Protein; D000818:Animals; D001066:Appetite / Q000187:drug effects; D002490:Central Nervous System / Q000378:metabolism*; D003345:Corticosterone / Q000097:blood; D004305:Dose-Response Relationship, Drug; D004435:Eating / Q000187:drug effects; D005938:Glucocorticoids / Q000502:physiology; D007276:Injections, Intraventricular; D036341:Intercellular Signaling Peptides and Proteins; D020738:Leptin / Q000008:administration & dosage; D008297:Male; D010456:Peptides, Cyclic / Q000008:administration & dosage; D011506:Proteins / Q000008:administration & dosage; D051381:Rats; D020318:Rats, Long-Evans; D044105:Receptor, Melanocortin, Type 4 / Q000378:metabolism; D044101:Receptors, Melanocortin / Q000502:physiology*; D020542:Third Ventricle; D000521:alpha-MSH / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000378:metabolism*
D054369:Agouti-Related Protein; D005938:Glucocorticoids; D036341:Intercellular Signaling Peptides and Proteins; D020738:Leptin; D010456:Peptides, Cyclic; D011506:Proteins; D044105:Receptor, Melanocortin, Type 4; D044101:Receptors, Melanocortin; C079282:melanotan-II; D000521:alpha-MSH; D003345:Corticosterone